The conditions of 26 women with cervical cancer who underwent 18F-FDG-PET before treatment with concurrent cisplatin and intensity-modulated radiation therapy were analyzed. BMACT was defined as the subregion of total bone marrow (BMTOT) with a standardized uptake value (SUV) equal to or above the mean for that individual. Inactive bone marrow (BMINACT) was defined as BMTOT 鈭?BMACT. Generalized linear modeling was used to test the correlation between BMACT and BMINACT dose-volume metrics and hematologic nadirs, particularly white blood cell count (WBC) and absolute neutrophil count (ANC).
Increased BMACT mean dose was significantly associated with decreased log(WBC)聽nadir (尾 = 鈭?.04; 95%CI, 鈭?.07to 鈭?.01; p = 0.009), decreased log(ANC) nadir (尾聽=聽鈭?.05; 95%CI, 鈭?.08 to 鈭?.02; p = 0.006), decreased hemoglobin nadir (尾 = 鈭?.16; 95%CI, 鈭?.27 to 鈭?.05; p = 0.010), and decreased platelet nadir (尾 = 鈭?.16; 95%CI, 鈭?.37 to 鈭?.96; p < 0.001). By contrast, there was no association between BMINACT mean dose and log(WBC) nadir (尾 = 鈭?.01; 95%CI, 鈭?.06 to 0.05; p = 0.84), log(ANC) nadir (尾 = 鈭?.03; 95%CI, 鈭?.10 to 0.04; p = 0.40), hemoglobin nadir (尾 = 鈭?.09; 95%CI, 鈭?.31 to 0.14; p聽=聽0.452), or platelet nadir (尾 = 鈭?.47; 95%CI, 鈭?0.44 to 3.50; p = 0.339).
Irradiation of BM subregions with higher 18F-FDG-PET activity was associated with hematologic toxicity, supporting the hypothesis that reducing dose to BMACT subregions could mitigate hematologic toxicity. Future investigation should seek to confirm these findings and to identify optimal SUV thresholds to define BMACT.